Interstitial Lung Disease in Lung Cancer: Separating Disease Progression from Treatment Effects

ISSN： 0114-5916

Source： Drug Safety, Vol.28, Iss.2, 2005-01, pp. : 103-113

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Cyclophosphamide for scleroderma interstitial lung disease

By Antoniu Sabina A

Expert Opinion on Investigational Drugs, Vol. 16, Iss. 3, 2007-03 ,pp. : 393-395

Informa Healthcare

Access to resources Recommend Favorite

Treatment strategies for a rheumatoid arthritis patient with interstitial lung disease

By Kelly Clive Saravanan Vadivelu

Expert Opinion on Pharmacotherapy, Vol. 9, Iss. 18, 2008-12 ,pp. : 3221-3230

Informa Healthcare

Access to resources Recommend Favorite

Recent Advances in the Treatment of Interstitial Lung Disease in Patients with Polymyositis/Dermatomyositis

Endocrine, Metabolic & Immune Disorders-Drug Targets (Formerly Current Drug Targets - Immune, Endocrine & Metabolic Disorders), Vol. 6, Iss. 4, 2006-12 ,pp. : 409-415

Bentham Science Publishers

Access to resources Recommend Favorite

Erlotinib: Fatal interstitial lung disease: case report

Reactions Weekly, Vol. 1, Iss. 1176, 2007-01 ,pp. : 14-14

Adis International

Access to resources Recommend Favorite

Gefitinib: Interstitial lung disease: case report

Reactions Weekly, Vol. 1, Iss. 1180, 2007-01 ,pp. : 18-18

Adis International

Access to resources Recommend Favorite